Measurement of Homing Receptors on the Surface of Leukemic and Nonleukemic Cell Lines

Hardy, Cheryl L.; Omoto, Eijiro; Tavassoli, Mehdi

doi:10.1159/000163580

Cited by 5 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason why this correlation was observed in PB but not in BM remains unclear. However, one possibility is that as the evolution to overt AML becomes imminent, preleukemic or leukemic blast cells tend to detach from the bone marrow stromal cells because of the alteration of adhesion molecules associated with the evolution to overt leukemia 19,20 and to flow into PB, resulting in an increase in WT1 expression levels in PB, but not a significant increase in the levels in BM.…”

Section: Discussionmentioning

confidence: 99%

The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes

Tamaki¹,

Ogawa²,

Ohyashiki³

et al. 1999

Leukemia

165

102

View full text Add to dashboard Cite

The Wilms' tumor gene, WT1, is a tumor marker for leukemic blast cells. The WT1 expression levels were examined for 57 patients with myelodysplastic syndromes (MDS) (refractory anemia (RA), 35; RA with excess of blasts (RAEB) 14; RAEB in transformation (RAEB-t), six; and MDS with fibrosis, two) and 12 patients with acute myeloid leukemia (AML) evolved from MDS. These levels significantly increased in proportion to the disease progression of MDS from RA to overt AML via RAEB and RAEB-t in both bone marrow (BM) and peripheral blood (PB). WT1 expression levels in PB significantly correlated with the evolution of RAEB or RAEB-t to overt AML within 6 months. Therefore, WT1 expression levels in PB were superior to those in BM for early prediction of the evolution to AML by means of quantitation of the WT1 expression levels. Furthermore, WT1 expression in PB of patients with overt AML evolved from MDS was significantly decreased by effective chemotherapy or allogeneic stem cell transplantation and became undetectable in long-term survivors. These results clearly showed that WT1 expression levels are a tumor marker for preleukemic or leukemic blast cells of MDS and thus reflect the disease progression of MDS. Therefore, monitoring of WT1 expression levels has made continuous assessment of the disease progression of MDS possible, as well as the prediction of the evolution of RAEB or RAEB-t to overt AML within 6 months. The results also showed that quantitation of WT1 expression levels is useful for diagnosis of minimal residual disease of MDS with high sensitivity, thus making it possible to evaluate the efficacy of treatment for MDS.

show abstract

Section: Discussionmentioning

confidence: 99%

The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes

Tamaki¹,

Ogawa²,

Ohyashiki³

et al. 1999

Leukemia

165

102

View full text Add to dashboard Cite

show abstract

Carbohydrate-dependent binding of human myeloid leukemia cell lines to neoglycoenzymes, matrix-immobilized neoglycoproteins, and bone marrow stromal cell layers

et al. 1994

View full text Add to dashboard Cite

The presence of sugar receptors on human myeloid leukemia cells was comparatively assessed by a highly sensitive binding assay, employing a panel of 14 types of neoglycoenzymes (chemically glycosylated Escherichia coli beta-galactosidase). The selected carbohydrate ligands mainly encompass common components of natural glycoconjugates as mono- or disaccharides. The monocytoid cells of the THP-1 line, the very young myeloblasts and the myeloblasts of the lines KG-1a and KG-1, the promyelocytes of the HL-60 line, and the early myeloblasts/erythroblasts of the K-562 line displayed a nonuniform pattern of specific binding with quantitative differences at a fixed, nonsaturating concentration of the probes. Scatchard analysis in four cases corroborated the indication of cell-type-related differences between the various cell lines. To test whether the detectable cellular sugar-binding sites can mediate adhesion to glycoligands, a rather simple model matrix of nitrocellulose-immobilized neoglycoproteins was first used. In comparison to the carbohydrate-free carrier protein significant cell adhesion was observed primarily with neoglycoproteins that exposed galactose, N-acetylgalactosamine, N-acetylglucosamine, mannose, and fucose moieties among the 11 tested types of carbohydrate residue. Subsequently, human bone marrow stromal cell layers were tested as a model matrix with increased levels of physiological relevance and complexity. Mixtures of carbohydrate and neoglycoprotein were employed as inhibitors of an interaction via lectins between the stromal and the tumor cells. The carbohydrate-dependent alterations of this parameter revealed cell-type-associated properties. Tumor cell binding was significantly decreased for not more than two lines with the effective sugars, namely N-acetylgalactosamine, mannose, fucose, and sialic acid.

show abstract

Role of bone marrow matrix in normal and abnormal hematopoiesis

Verfaillie

Hurley

Bhatia

et al. 1994

Critical Reviews in Oncology/Hematology

113

View full text Add to dashboard Cite

Measurement of Homing Receptors on the Surface of Leukemic and Nonleukemic Cell Lines

Cited by 5 publications

References 7 publications

The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes

The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes

Carbohydrate-dependent binding of human myeloid leukemia cell lines to neoglycoenzymes, matrix-immobilized neoglycoproteins, and bone marrow stromal cell layers

Role of bone marrow matrix in normal and abnormal hematopoiesis

Contact Info

Product

Resources

About